Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.4M | $36.6M | $84.5M | $102M | $118M | $111M | $111M | $176M | $57.8M | $39.6M |
| Revenue growth | — | 88.6% | 131.0% | 21.3% | 15.4% | -6.3% | 0.5% | 58.3% | -67.2% | -31.6% |
| Operating income | -$72.6M | -$56.4M | -$77.2M | -$105M | -$130M | -$183M | -$201M | -$274M | -$104M | -$121M |
| Operating margin | -374.2% | -154.1% | -91.4% | -102.7% | -109.6% | -165.6% | -180.8% | -155.5% | -179.9% | -306.5% |
| Net income | -$71.7M | -$54.6M | -$68.3M | -$95.2M | -$121M | -$178M | -$192M | -$258M | -$97.9M | -$123M |
| Net margin | -369.6% | -149.2% | -80.9% | -92.9% | -102.4% | -161.1% | -172.8% | -146.3% | -169.4% | -310.8% |
| EPS (diluted) | -$1.02 | -$0.70 | -$0.70 | -$0.85 | -$0.90 | -$1.23 | -$1.25 | -$1.48 | -$0.49 | -$0.44 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$65.9M | $11.2M | $36.5M | -$144M | $170M | -$233M | -$224M | -$225M | -$67.1M | -$97.2M |
| Capital expenditures | $732K | $3.75M | $43.1M | $20.7M | $14.7M | $23.3M | $20.2M | $21.2M | $267K | $102K |
| Free cash flow | -$66.6M | $7.43M | -$6.51M | -$165M | $155M | -$257M | -$244M | -$246M | -$67.4M | -$97.3M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $22.1M | $49.8M | $140M | $80.4M | $131M | $179M | $100M | $45.2M | $41.9M | $20.9M |
| Total assets | $158M | $287M | $590M | $638M | $939M | $722M | $563M | $165M | $102M | $59.7M |
| Total liabilities | $21.7M | $98.8M | $223M | $205M | $441M | $347M | $268M | $82.4M | $78.9M | $74.0M |
| Shareholders' equity | $136M | $188M | $367M | $433M | $498M | $375M | $295M | $82.9M | $22.8M | -$14.3M |
| Retained earnings | -$441M | -$495M | -$563M | -$657M | -$778M | -$956M | -$1.15B | -$1.41B | -$1.50B | -$1.63B |
| Shares (wtd avg diluted) | 70.9M | 85.6M | 102M | 112M | 134M | 145M | 154M | 174M | 202M | 280M |
Every figure is extracted from SANGAMO THERAPEUTICS, INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.